As IDH1-wt gliomas exhibit increased PD-L1 expression and greater TIL infiltration, those tumors are considered to be more immunologically active and more susceptible to immunomodulatory therapy against PD-1/PD-1L than IDH-mut gliomas. The gene discussed is IDH1; the disease is central nervous system cancer.